Tezepelumab PRO study - TezepelumabPRO

Study identifier:D5180R00025

ClinicalTrials.gov identifier:NCT05922891

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Effectiveness of Tezepelumab on Asthma control and Cough: A prospective, multi-center, observational study

Medical condition

asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

90

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 27 Sept 2023
Estimated Primary Completion Date: 30 Sept 2025
Estimated Study Completion Date: 30 Sept 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria